[6] Managed by the Department of State's Bureau for Global Health Security and Diplomacy, PEPFAR funding is detailed in annual congressional appropriations and also supports agencies like USAID, CDC, and DoD.
[10] Later in the day on January 28th, the Trump administration issued a waiver for critical medicines and medical services, reinstating a global HIV treatment program that had been halted the previous week.
[15] However, this funding is only a fraction—just 25%—of the $5 billion annual goal set during a United Nations High-Level Meeting on TB aimed at ending the epidemic by 2030.
Global Fund investments have led to a 61% reduction in deaths from HIV, tuberculosis, and malaria since 2002, saving 65 million lives according to a 2024 analysis.
[20] The Global Fund’s latest report highlights a 55% price reduction for bedaquiline, a key drug for treating drug-resistant tuberculosis, and a 25% drop in the cost of tenofovir disoproxil fumarate, lamivudine, and dolutegravir (TLD), the first-line treatment for HIV.
[22] On January 20, 2025, immediately after being sworn in for his second term, U.S. President Donald Trump issued an executive order to begin the process of withdrawing the United States from the World Health Organization (WHO).
[23] This move carries significant consequences for global health, given that the U.S. has traditionally been the WHO’s largest financial supporter, contributing more than $10 billion in the previous fiscal year and accounting for roughly 18% of its total budget.
"[25] Anand Reddi and Sarah Leeper rebutted Emanuel by stating "The idea that differing global health initiatives must compete with each other lacks not only ethical legitimacy but also scientific merit.
Confronting illness in isolation -- whether by funding PEPFAR at the expense of programs that target maternal or child health or vice versa -- cannot be our way forward.
[27] The United States has provided an additional $17 million USD to support clade I mpox preparedness and response in Central and Eastern Africa.
[28] This funding is focused on enhanced surveillance, risk communication, community engagement, laboratory supplies, diagnostics, clinical services, and vaccine planning.